Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
JIB
BioConferenceLive

New Drugs Block Synthesis of Metabolites by Nutrient-Challenged Bacteria

By BiotechDaily International staff writers
Posted on 24 Oct 2013
Researchers have developed a new generation of antibiotics that kill bacteria by preventing them from making critical metabolites such as vitamins and amino acids.

Characterizing new drugs has been hindered by the difficulties inherent in identifying the mechanism of action (MOA) of biologically active molecules. To attack this problem, investigators at McMaster University (Hamilton, ON, Canada) developed a metabolite suppression approach to explore the MOA of antibacterial compounds under conditions of nutrient restriction.

They assembled an array of metabolites that could be screened for suppressors of inhibitory molecules. Further, they identified inhibitors of Escherichia coli growth under nutrient limitation and charted their interactions with the metabolite array. This strategy led to the discovery and characterization of three new antibacterial compounds, MAC168425 (3-(dimethylamino)-1-(4-methoxyphenyl)propan-1-one), MAC173979 (3,3-dichloro-1-(3-nitrophenyl)prop-2-en-1-one), and MAC13772 (2-(2-nitrophenylthio)acetohydrazide). MAC168425 was found to interfere with glycine metabolism, MAC173979 was a time-dependent inhibitor of p-aminobenzoic acid biosynthesis, and MAC13772 inhibited biotin biosynthesis. These findings were published in the October 13, 2013, online edition of the journal Nature Chemical Biology.

"We have developed technology to find new antibiotics using laboratory conditions that mimic those of infection in the human body," said senior author Dr. Eric Brown, professor of biochemistry and biomedical sciences at McMaster University.

"We are taking fresh aim at bacterial vitamin and amino acid production and finding completely novel antibacterial compounds," said Dr. Brown. "We threw away chemicals that blocked growth in conventional nutrient-rich conditions and focused instead on those that were only active in nutrient-poor conditions. The approach belies conventional thinking in antibiotic research and development, where researchers typically look for chemicals that block growth in the laboratory under nutrient-rich conditions, where vitamins and amino acids are plentiful, but in the human body these substances are in surprisingly short supply and the bacteria are forced to make these and other building blocks from scratch."

Related Links:

McMaster University



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: Microcomputed tomography images (top) and histology images (bottom) of the knees of mice fed a very high fat diet containing omega-3 fatty acid supplement (left) or only omega-6 fatty acids (right) after a knee injury. The omega-6 diet showed abnormal bone remodeling and calcified tissue formation in the joint (white arrow). The omega-6 diet also showed significant loss of cartilage (red staining, yellow arrowhead) and increased joint inflammation (Photo courtesy of Duke University).

Dietary Omega-3 Fatty Acids Moderate Severity of Osteoarthritis in a Mouse Model

Researchers working with an osteoarthritis (OA) obese mouse model found that the fat content of the animals' diet contributed more to the development or arrest of OA than did body weight.... Read more

Therapeutics

view channel

Vaccine Being Developed for Heart Disease Close to Reality

The world’s first vaccine for heart disease is becoming a possibility with researchers demonstrating significant arterial plaque reduction in concept testing in mice. Klaus Ley, MD, from the La Jolla Institute for Allergy and Immunology (LA Jolla, CA, USA), and a vascular immunology specialist, is leading the vaccine... Read more

Business

view channel

A Surge in IPOs Revitalize Investments for the Global Pharma and Biotech

Anti-infective drugs, oncology, and pharmaceutical contract laboratories attract the most investment up to now. The intensified private equity and venture capital (PEVC) deal activity in the global healthcare industry during the recession years, 2008–2010, witnessed a waning post-2010. However, the decline in deals... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.